Register now for Fin24 Dashboard and get access to portfolios, watchlists, financial comparison tools, and a whole lot more to help you achieve your financial goals.

Data provided by McGregor BFA
All data is delayed
Loading...
Where am I? Home
 
Prices are delayed by 15min.
Join the Fin24.com conversation about JSE-listed stock by using every time you tweet.

Health stocks just the right tonic

Feb 16 2010 07:31 Letitia Watson

Related Articles

Adcock eyes new opportunities

Aspen Pharmacare stocks jump

Medi-Clinic keeps up the growth

Netcare a defensive pick

Netcare group to list in UK

Health stocks tipped to bloom

 

Top Stories

Cell C move sparks price war

May 27 2012 11:21

There's a price war raging between South Africa's cellphone networks after Cell C lowered the rates of its prepaid calls by more than 34%.

MyCiti buses running at a loss

May 28 2012 07:53

The City of Cape Town has spent R175m running the Myciti bus service since the Soccer World Cup compared to an income of R35m, a report says.

Another golf estate victim

May 27 2012 13:09

The oversupply of golf estates has claimed another victim.

 
Share Share line Print

Cape Town - Because of their defensive nature, health-related companies have performed reasonably well during the economic downturn.

Abdul Davids, head of research at Kagiso Asset Management, says health companies are dependent on government decisions about the industry - which in turn can affect their valuations. There is currently no certainty as to when the national health insurance (NHI) system will realise and how it could affect companies.

In general, Medi-Clinic's market risk is lower, while Netcare, according to Davids, has better growth potential. Medi-Clinic is well diversified with its Swiss interests, in particular, that are doing well.

Netcare is also strong offshore because of its interests in the United Kingdom. This group's big balance-sheet debt is being discharged, which will improve revenue growth.

Davids reckons Netcare and Medi-Clinic are attractive at current levels.

Pharmaceutical groups with a strong focus on generic medicines like Cipla Medpro and Adcock will probably benefit from the NHI.

Among local companies Cipla has the best capacity to increase its production of generics, expanding its growth potential.

According to Davids, Cipla and Aspen's earnings-growth prospects indicate a possible doubling over the next two to three years.

He reckons that Cipla in particular has good potential from the perspective of dividends and capital growth.

- Fin24.com

For more business news in Afrikaans, got to Sake24.com.

 
 
Comment on this story
0 comments
Add your comment
Comment 0 characters remaining
It pays to know the cost and what you’re getting in return
May 28 2012 09:33

Investors may not have a clue what they’re paying their money managers or they type of service they’re getting, or, whether they can actually negotiate lower fees. (Reuters)

Sasha

"In the short term this is true, Greece will dominate the headlines on a day to day basis, until their next elections when there would be some clarity to answer the question, "What next for Greece?" Amazingly everyone except the politicians seem to be lining themselves up for worst case scenario, b... Read their blog...

Recently updated
Podcasts
The Sishen saga

Legal expert Peter Leon on the increasingly complex legal wrangle over the Sishen Iron Ore mine. Time: 8:17 Listen Here...

Before you list

Is the clarion call of the JSE calling? Listen to Fin24’s expert panel discussion before you list your small business. Time: 17:29

Compare and Buy

Compare and apply for hundreds of financial products from many suppliers.

Credit cards Medical aid Current accounts Think Money

Money Clinic

Money Clinic Do you have a question about your finances? We'll get an expert opinion.
Click here...

Loading...